Aquaporin-2 water channels and vasopressin antagonists in edematous disorders

Molecular Genetics and Metabolism

Volumn 65, Issue 4, 1998, Pages 255-263

  Schrier, Robert W ^a   Ohara, Mamiko ^a   Rogachev, Boris ^a   Xu, Lieming ^a   Knotek, Mladen ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN; ARGIPRESSIN; LIXIVAPTAN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VPA 958;

ASCITES; BODY FLUID; CONGESTIVE HEART FAILURE; DRUG EFFECT; EDEMA; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; MEMBRANE CHANNEL; NEUROENDOCRINE SYSTEM; NONHUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY; VASODILATATION; WATER TRANSPORT;

EID: 0032417044     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1998.2765     Document Type: Article

References (56)

1. Starling E H. Fluids of Body. 1909;Keener, Chicago.
2. Schrier R W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med. 319:1988;1065-1072.
3. Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 8:1988;1151-1157.
4. Schrier R W. Body fluid volume regulation in health and disease: A unifying hypothesis. Ann Intern Med. 113:1990;155-159.
5. Schrier R W, Briner V A. Peripheral arterial vasodilation hypothesis of sodium and water retention in pregnancy: Implications for pathogenesis of preeclampsia-eclampsia. Obstet Gynecol. 77:1991;632-639.
6. Schrier R W. An odyssey into the milieu interieur: Pondering the enigmas. J Am Soc Nephrol. 2:1992;1549-1559.
7. Szatalowicz V L, Arnold P E, Chaimovitz C, Bichet D, Berl T, Schrier R W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 305:1981;263-266.
8. Pruszczynski W, Vahanian A, Arnold R, Acar J. Role of antidiuretic hormone in impaired water excretion of patients with congestive cardiac failure. J Clin Endocrinol Metab. 58:1984;599-605.
9. Goldsmith S R, Francis G S, Cowley A W. Arginine AVP and the renal response to water loading in congestive cardiac failure. Am J Cardiol. 58:1986;295-299.
10. Lee W H, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 73:1986;257-267.
11. Haskins G J, Esler M D, Jenning G L, Burton D, Korner P I. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 73:1986;615-621.
12. Land H, Schutz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginie vasopressin-neurophysin II precursor. Nature. 295:1982;299-303.
13. Ivell R, Richter D. Structure and comparison of the oxytocin and vasopressin genes from rat. Proc Natl Acad Sci USA. 81:1984;2006-2010.
14. Rehbein M, Hillers M, Mohr E, Ivell R, Morley S, Schmale H, Richter D. The neurohypophyseal hormones vasopressin and oxytocin. Biol Chem Hoppe-Seyler. 367:1986;695-704.
15. Kim J K, Summer S N, Wood W M, Brown J L, Schrier R W. Arginine vasopressin secretion with mutants of wild-type and Brattleboro rats AVP gene. J Am Soc Nephrol. 8:1997;1863-1869.
16. Kim J K, Michel J B, Soubrier F, Durr J, Corvol P, Schrier R W. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int. 38:1990;818-822.
17. Lolait S J, O'Carroll A-M, McBride O W, Konig M, Brownstein M J. Cloning and characterization of a AVP V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 357:1992;336-339.
18. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor of human antidiuretic hormone. Nature. 357:1992;333-335.
19. Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus M F, Hendy G N, Birnbaumer M, Bichet D. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 359:1992;233-235.
20. van den Ouweland A M, Dreesen J C, Verdijk M, Knoers N V, Monnens L A, Rocchi M, van Oost B A. Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus. Nature Genet. 2:1992;99-102.
21. Pan Y, Metzenberg A, Das S, Jing B, Gitschier J. Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nature Genet. 2:1992;103-106.
22. Ishikawa S, Saito T, Okuda K, Tsutsui K, Kuzuya T. Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. Kidney Int. 30:1986;49-55.
23. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 105:1992;787-791.
24. Xu D-L, Martin P-Y, Ohara M, St. John J, Pattison T, Meng X, Morris K, Kim J K, Schrier R W. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 99:1997;1500-1505.
25. Abraham W T, Oren R M, Robertson A D, Schrier R W. Effects of an oral, non-peptide, selective AVP antagonist in human heart failure. Nephrology. 3:1997;S15.
26. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 361:1993;549-552.
27. Uchida S, Sasaki S, Fushimi K, Marumo F. Isolation of human aquaporin-CD gene. J Biol Chem. 269:1994;23451-23455.
28. Marples D, Knepper M A, Christensen E I, Nielsen S. Redistribution of aquaporin-2 water channels induced by vasopressin in rat kidney inner medullary collecting duct. Am J Physiol. 269:1995;C655-C664.
29. Nielsen S, L. C C, Marples D, Christensen E I, Kishore B K, Knepper M A. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA. 92:1995;1013-1017.
30. Yamamoto T, Sasaki S, Fushimi K, Ishibashi K, Yaoita E, Kawasaki K, Marumo F, Kihara I. Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. Am J Physiol. 268:1995;C1546-C1551.
31. van Os C H, Deen P MT. Role of aquaporins in renal water handling: physiology and pathophysiology. Nephrol Dial Transplant. 13:1998;1645-1651.
32. Deen P M, Verdijk M A, Knoers N V, Wieringa B, Monnens L AH, van Os C H, van Oost B A. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 264:1994;92-95.
33. Martin P-Y, Abraham W T, Xu L, Oren R M, Olson B R, Ohara M, Schrier R W. Selective V2 receptor AVP antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 8:1997;A0103.
34. Bichet D G, Kortas C, Mettauer B, Manzini C, Marc-Aurele J, Rouleau J L, Schrier R W. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int. 29:1986;1188-1196.
35. CONSENSUS TSG. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavia Enalapril Survival Study (CONSENSUS). N Engl J Med. 325:1987;1429-1435.
36. Ruffolo R RJ, Feuerstein G Z, Ohlstein E H. Recent observations with betaadrenoceptor blockade. Am J Hyperten. 11:1998;9S-14S.
37. Nicod P, Waeber B, Bussien J P, Goy J J, Turini G, Nussberger J, Hofbauer K G, Brunner H R. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol. 55:1985;1043-1047.
38. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T. Effect of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 267:1994;H2245-H2254.
39. Johnston C I, Arnolda L, Abrahams J, McGrath B. Role of vasopressin in experimental congestive cardiac failure. J Cardiovasc Pharmacol. 8:1986;S96-100.
40. Okada K, Ishikawa S, Caramelo C, Tsai P, Schrier R W. Enhancement of vascular action of arginine vasopressin by diminished extracellular sodium concentration. Kidney Int. 44:1993;755-763.
41. Riegger G A, Liebau G, Bauer E, Kochsiek K. Vasopressin and renin in high output heart failure of rats: hemodynamic effects of elevated plasma hormone levels. J Cardiovasc Pharmacol. 7:1985;1-5.
42. Papper S. The role of the kidney in Laennec's cirrhosis of the liver. Medicine (Baltimore). 37:1958;299-316.
43. Lieberman F L, Denison E K, Reynolds T B. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: the overflow theory of ascites formation. Ann NY Acad Sci. 170:1970;202-212.
44. Henriksen J H, Bendtsen F, Sorensen I T, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology. 97:1989;1506-1513.
45. Bichet D, Szatalowicz V, Chaimovitz C, Schrier R W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 96:1982;413-417.
46. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, Jimenez W, Gaya J, Rivera F, Rodes J. Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 84:1988;482-487.
47. Kim J K, Summer S N, Howard R L, Schrier R W. Vasopressin gene expression in rats with experimental cirrhosis. Hepatology. 17:1993;143-147.
48. Claria J, Jimenez W, Arroyo V. Blockade of the hydro-osmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology. 97:1989;1294-1299.
49. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int. 46:1994;237-244.
50. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, Castro A, Gaya J, Rivera F, Rodes J. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology. 100:1991;494-501.
51. Fujita N, Ishikawa S E, Sasaki S, Fujisawa G, Fushimi K, Marumo F, Saito T. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 269:1995;F926-931.
52. Shapiro M D, Nicholls K M, Groves B M, Kluge R, Chung H M, Bichet D G, Schrier R W. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int. 28:1985;206-211.
53. Martin P-Y, Ohara M, Gines P, Xu D-L, St John J, Niederberger M, Schrier R W. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 101:1998;235-242.
54. Durr J A, Stamoutsos B, Lindheimer M D. Osmoregulation during pregnancy in the rat: Evidence for resetting of the threshold for vasopressin secretion during gestation. J Clin Invest. 68:1981;337-346.
55. Davison J M, Vallotton M B, Lindheimer M D. Plasma osmolality and urinary concentration and dilution during and after pregnancy: Evidence that lateral recumbency inhibits maximal urinary concentrating ability. Br J Obstet Gynaecol. 88:1981;472-479.
56. Ohara M, Martin P-Y, Xu D-L, St John J, Pattison T A, Kim J K, Schrier R W. Upregulation of aquaporin 2 water channel expression in pregnant rats. J Clin Invest. 101:1998;1076-1083.